Sutro Biopharma, Inc. STRO

STRO Company Overview

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on developing engineered therapeutics for oncology and autoimmune diseases. The company operates within the biopharmaceutical and antibody therapeutics industries, with a primary emphasis on antibody-drug conjugates (ADCs), bispecific antibodies, and cell-free protein synthesis technologies. Sutro’s core differentiator is its proprietary XpressCF® platform, a cell-free protein synthesis system designed to enable precise and scalable engineering of biologic medicines, including site-specific ADCs with optimized therapeutic properties.

The company’s primary revenue drivers have historically included collaboration agreements, licensing arrangements, and research partnerships with larger pharmaceutical companies, alongside milestone payments and limited product-related revenue due to its clinical-stage status. Sutro was founded in 2003 and evolved from a platform technology company into a therapeutics developer with a pipeline centered on oncology targets. Over time, it expanded from technology licensing into internally developed clinical assets while maintaining strategic collaborations with global pharmaceutical companies.